Company intelligence / Profile preview

Swiss Medica

Belgrade, Serbiamstreatment-europe.com ↗

Ownership: Private
Development stage: Commercial

Overview

Swiss Medica has treated over 10,000 patients from more than 70 countries with stem cell therapies for a range of chronic, neurological, autoimmune, and orthopedic conditions. Reported outcomes include reduced pain, improved motor control and mobility, fewer symptom flare-ups, greater independence in daily life, and overall better quality of life. The company emphasizes personalized care combining mesenchymal stem cells with supportive therapies to enhance regenerative potential

Therapeutic areas: EndocrinologyPsychiatryNeurology
Modalities: Stem cell therapy (specifically Mesenchymal stem cells)Cell therapyRegenerative medicine approaches
Industry: Non-Academic Healthcare

Beyond the preview

Go deeper on Swiss Medica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Swiss Medica.

Explore the full profile